341 related articles for article (PubMed ID: 782834)
1. Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.
Pinder RM; Brogden RN; Sawyer PR; Speight TM; Avery GS
Drugs; 1976; 11(5):329-77. PubMed ID: 782834
[No Abstract] [Full Text] [Related]
2. [Somatosensory evoked potentials in patients with parkinsonism during L-dopa decarboxylase inhibitor treatment].
Koziel H; Kuran W; Zakrzewska F
Neurol Neurochir Pol; 1977; 11(1):73-80. PubMed ID: 840365
[No Abstract] [Full Text] [Related]
3. Comparison of levodopa with carbidopa or benserazide in parkinsonism.
Greenacre JK; Coxon A; Petrie A; Reid JL
Lancet; 1976 Aug; 2(7982):381-4. PubMed ID: 73849
[TBL] [Abstract][Full Text] [Related]
4. [Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].
Mizuno Y; Yoshida M; Obayashi T; Ueki A
Rinsho Shinkeigaku; 1976 Jul; 16(7):511-9. PubMed ID: 986921
[No Abstract] [Full Text] [Related]
5. Treatment of Parkinson's disease with carbidopa, a peripheral decarboxylase inhibitor, and levodopa.
Fermaglich J
Med Ann Dist Columbia; 1974 Dec; 43(12):587-91. PubMed ID: 4532167
[No Abstract] [Full Text] [Related]
6. [CB 154 in the treatment of Parkinson's disease. Results in combination with L-dopa and decarboxylase inhibitor].
Meco G; Casacchia M; Zamponi A; Agnoli A
Acta Neurol (Napoli); 1976; 31(4):479-48. PubMed ID: 1037427
[No Abstract] [Full Text] [Related]
7. Levodopa with benserazide or carbidopa in Parkinson disease.
Rinne UK; Mölsä P
Neurology; 1979 Dec; 29(12):1584-9. PubMed ID: 574221
[TBL] [Abstract][Full Text] [Related]
8. Parkinson's disease treated with Sinemet or Madopar. A controlled multicenter trial.
Pakkenberg H; Birket-Smith E; Dupont E; Hansen E; Mikkelsen B; Presthus J; Rautakorpi I; Riman E; Rinne UK
Acta Neurol Scand; 1976 May; 53(5):376-85. PubMed ID: 1266576
[TBL] [Abstract][Full Text] [Related]
9. [Clinical significance of cramps of the lower extremities in patients with parkinsonism].
Yu HZ
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):217-8. PubMed ID: 4075911
[No Abstract] [Full Text] [Related]
10. [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
Podiwinsky F; Mentasti M; Riederer P; Birkmayer W
Wien Klin Wochenschr; 1979 May; 91(10):332-7. PubMed ID: 452602
[TBL] [Abstract][Full Text] [Related]
11. Combined use of benserazide and carbidopa in Parkinson's disease.
Lieberman AN; Goldstein M; Gopinathan G; Neophytides A; Hiesiger E; Walker R; Nelson J
Neurology; 1984 Feb; 34(2):227-9. PubMed ID: 6538015
[TBL] [Abstract][Full Text] [Related]
12. Treating parkinsonism with L-dopa and carboxylase inhibitor.
Shau-Fong K; Ho YM
Mod Med Asia; 1977 Sep; 13(9):23-5. PubMed ID: 600260
[No Abstract] [Full Text] [Related]
13. Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia.
Horstink MW; Zijlmans JC; Pasman JW; Berger HJ; van't Hof MA
J Neurol Neurosurg Psychiatry; 1990 Mar; 53(3):224-6. PubMed ID: 2324754
[TBL] [Abstract][Full Text] [Related]
14. Ethanol, levodopa and inhibitors of extracerebral aromatic L-amino acid decarboxylase: a drug-drug interaction study.
Messiha FS
Proc West Pharmacol Soc; 1977; 20():327-31. PubMed ID: 896840
[No Abstract] [Full Text] [Related]
15. [Development of studies on the treatment of Parkinson syndromes using levodopa. I. Short- and medium-term (2 years) effects of the combination levodopa decarboxylase inhibitor].
Rondot P; Ribadeau Dumas JL; Cardon P
Therapie; 1975; 30(5):653-66. PubMed ID: 769245
[No Abstract] [Full Text] [Related]
16. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of Parkinson's syndromes by a combination of levodopa with decarboxylase inhibitors].
Hanzal F
Cesk Neurol Neurochir; 1975 Dec; 38(6):327-32. PubMed ID: 1192544
[No Abstract] [Full Text] [Related]
18. [Carbidopa-levodopa, growth hormone and parkinsonism].
Marti-Masso JF; Carrera N; Martínez-Lage JM
Rev Clin Esp; 1976 Jun; 141(6):525-32. PubMed ID: 968087
[No Abstract] [Full Text] [Related]
19. [Development of studies on the treatment of parkinsonian syndromes with levodopa. II. Long-term effects of L-DOPA alone or in combination with a decarboxylase inhibitor].
Rabadeau Dumas JL; Rondot P; Cardon P
Therapie; 1977; 32(2):161-72. PubMed ID: 898124
[No Abstract] [Full Text] [Related]
20. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
Fung VS; Herawati L; Wan Y; ;
Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
